We are live on ! Find out more
BCAX

Bicara Therapeutics
BCAX

146 hedge funds and large institutions have $1.4B invested in Bicara Therapeutics in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 58 increasing their positions, 40 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 40

39% more capital invested

Capital invested by funds: $1.01B → $1.4B (+$390M)

38% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 21

23.56% more ownership

Funds ownership: 106.52% → 130.08% (+24%)

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

4% more funds holding

Funds holding: 141 → 146 (+5)

62% less call options, than puts

Call options by funds: $1.52M | Put options by funds: $4M

Holders
146
Holders Change
+5
Holders Change %
+3.55%
% of All Funds
1.8%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.1%
New
29
Increased
58
Reduced
40
Closed
21
Calls
$1.52M
Puts
$4M
Net Calls
-$2.48M
Net Calls Change
+$809K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$58M
2
VPC
Vestal Point Capital
New York
+$31.8M
3
DTC
Deep Track Capital
Connecticut
+$24.9M
4
RPSM
Royalty Pharma Sub-Manager
New York
+$19.4M
5
HP
HealthInvest Partners
Sweden
+$18.2M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$21.5M
2
Millennium Management
Millennium Management
New York
-$4.79M
3
State Street
State Street
Massachusetts
-$3.96M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.16M
5
SCM
Soleus Capital Management
Connecticut
-$1.68M
Name Holding Trade Value Shares
Change 		Change in
Stake
BGM
51
Burkehill Global Management
New York
$1.99M +$1.72M +100,000 New
Manulife (Manufacturers Life Insurance)
52
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.8M -$149K -8,633 -9%
Two Sigma Investments
53
Two Sigma Investments
New York
$1.79M -$148K -8,600 -9%
Bank of New York Mellon
54
Bank of New York Mellon
New York
$1.66M -$93.2K -5,413 -6%
SC
55
Shay Capital
New York
$1.26M -$13.8K -800 -1%
SGM
56
Seven Grand Managers
New York
$1.24M +$1.08M +62,500 New
MAM
57
Martingale Asset Management
Massachusetts
$1.14M +$990K +57,538 New
Mariner
58
Mariner
Kansas
$1.09M -$164K -9,525 -15%
Swiss National Bank
59
Swiss National Bank
Switzerland
$1.09M +$391K +22,700 +70%
SCM
60
SCS Capital Management
Massachusetts
$1.06M – – –
AA
61
ALPS Advisors
Colorado
$1.03M +$114K +6,602 +15%
American Century Companies
62
American Century Companies
Missouri
$1.03M +$466K +27,060 +110%
SLAM
63
Swiss Life Asset Management
$979K +$149K +8,651 New
N
64
Nuveen
North Carolina
$875K +$88.5K +5,143 +13%
RhumbLine Advisers
65
RhumbLine Advisers
Massachusetts
$810K +$2.82K +164 +0.4%
BNP Paribas Financial Markets
66
BNP Paribas Financial Markets
France
$803K -$955K -55,505 -58%
HF
67
HRT Financial
New York
$799K -$171K -9,938 -20%
Rafferty Asset Management
68
Rafferty Asset Management
New York
$756K -$376K -21,816 -36%
Invesco
69
Invesco
Georgia
$630K +$183K +10,644 +51%
BFG
70
Bleakley Financial Group
New Jersey
$583K +$2.56K +149 +0.5%
Barclays
71
Barclays
United Kingdom
$573K -$1.28M -74,418 -72%
Prudential Financial
72
Prudential Financial
New Jersey
$544K +$470K +27,330 New
AllianceBernstein
73
AllianceBernstein
Tennessee
$536K +$46.8K +2,720 +9%
OF
74
Optimize Financial
California
$477K +$413K +23,996 New
VAM
75
Vanguard Asset Management
$476K +$412K +23,943 New
1 2
3
4 5

BCAX Hedge Fund Activity: Q1 2026 in Review

146 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Bicara Therapeutics (BCAX) for Q1 2026, worth a combined $1.4B — up 39% from $1.01B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new BCAX positions and 21 closed out — a net gain of 8 holders — while 58 added to existing stakes and 40 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $58M. The largest seller was Fidelity Investments, cutting an estimated $21.5M.

  • 146 institutional investors held Bicara Therapeutics (BCAX) as of Q1 2026, up from 141 in Q4 2025.
  • Funds reported $1.4B of Bicara Therapeutics stock for Q1 2026, up 39% quarter-over-quarter.
  • 29 funds opened new Bicara Therapeutics positions in Q1 2026 and 21 closed out, a net change of +8 holders.
  • The largest Bicara Therapeutics buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $58M added.
  • The largest Bicara Therapeutics seller in Q1 2026 was Fidelity Investments, an estimated $21.5M sold.

Based on aggregated 13F filings for Q1 2026.